Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Autoimmune myelofibrosis (AIMF) is a nonmalignant bone marrow fibrosis linked to autoimmune diseases.
• Patients present with cytopenias, autoantibodies, and nonclonal myelofibrosis without typical primary myelofibrosis features.
• AIMF is often underrecognized and distinct from malignant conditions.

Purpose of the Study:

• To characterize the clinical presentation and outcomes of patients diagnosed with AIMF.
• To evaluate the effectiveness of various therapies for AIMF.

Main Methods:

• A retrospective chart review was conducted at a single institution.
• Data collected included clinical presentations, treatments, and patient outcomes.
• Twelve patients diagnosed with AIMF were included in the analysis.

Main Results:

• The study identified 12 patients with AIMF, followed for a mean of 5.8 years.
• All patients had autoantibodies, and most had co-existing autoimmune disorders.
• Immunosuppressive therapy led to complete or partial responses in cytopenias for 7 patients.

Conclusions:

• AIMF is a significant contributor to cytopenias in patients with autoimmune disorders.
• The majority of AIMF patients show improvement in cytopenias with immunosuppressive therapy.
• No patients developed myeloproliferative neoplasms during follow-up.